PMCPA Case Library

Every PMCPA ruling since 2005 — searchable and filterable by company, clause, and ABPI Code version.

1,930
Cases
291
Companies
154
Clauses
6
Code Versions

or browse all 154 ABPI clause guides ↗

Case Library Membership

Filter by Company & ABPI Clause

Search free — but unlock advanced filters to find every case involving a specific company or clause.

Filter 1,930+ cases by any of 291 companies
Filter by any of 154 ABPI Code clauses
Filter by Code version (2016, 2019, 2021…)
Full-text keyword search across all cases
Cancel any time

Already a member? Sign in →

Case Library Membership

Best value
£249 /year Save £99

inc. VAT

£29 /month

inc. VAT · cancel any time

Unlock Full Access →

Secure payment via Stripe


Need access for your team?

Company licences available for compliance teams, medical affairs, and training programmes.

Get a team quote →

1,930 cases found

2021
CASE
2021 Code Novartis Clause 5.1 Clause 6.1 Clause 6.2

Novartis breached ABPI Code over Jakavi webpage claim implying statistically significant survival benefit vs BAT

PMCPA found Novartis’ Jakavi HCP webpage claim “Improved survival benefit compared with BAT” misleading and unsubstantiated because it implied statistically significant survival…

2022
CASE
2021 Code AstraZeneca Clause 5.1 Clause 11.2 Clause 26.1

AstraZeneca: UK employees’ LinkedIn ‘likes’ treated as proactive dissemination of US Enhertu post (AUTH/3687/8/22)

Eight UK-based AstraZeneca employees ‘liked’ a US LinkedIn post linking to an Enhertu press release. The PMCPA ruled this proactively disseminated promotional…

2022
CASE
2021 Code Amgen Clause 5.1 Clause 10.9

Amgen: sponsorship not clear “at the outset” in third-party webinar invite and infographic (AUTH/3702/10/22)

Amgen-sponsored webinar invite and downloadable infographic looked like they were from an independent organisation. Sponsorship disclosure appeared too late and wording was…

2022
CASE
2021 Code AstraZeneca

AUTH/3613/2/22: Complainant v AstraZeneca — LinkedIn promotion allegation and alleged breach of undertaking (out of scope)

Complaint alleged LinkedIn promotion and breach of an undertaking by AstraZeneca. PMCPA concluded the matter was outwith the scope of the ABPI…

2022
CASE
2021 Code Eli Lilly

Eli Lilly Trulicity promotional email: “significant” HbA1c/weight and CV risk reduction claims found not misleading (AUTH/3686/8/22)

Complaint alleged Trulicity email claims were unclear on comparator, patient details and statistical significance, and that a secondary endpoint (weight) was presented…

2022
CASE
2021 Code Sandoz Clause 5.1 Clause 19.2

Sandoz: Omnitrope cool bag exceeded £10 limit and withdrawal not communicated proactively (AUTH/3685/8/22)

Sandoz supplied an Omnitrope cool bag costing £13.66 (over the £10 limit) and later withdrew it without proactive stakeholder communication. Breaches of…

2022
CASE
2021 Code Novartis Pharmaceuticals UK Clause 5.1 Clause 8.3

Novartis: MailOnline MS disease-awareness article—share-button templates not certified (AUTH/3662/6/22)

Novartis certified a MailOnline MS disease-awareness article, but the PMCPA found the social share templates generated by share buttons weren’t certified. Breach…

2021
CASE
2021 Code Astellas Pharma Clause 1 Clause 5

Astellas voluntary admission: transfers of value not disclosed to HCOs and patient organisations (2019–2021)

Astellas self-reported undisclosed transfers of value to two healthcare organisations and five patient organisations (2019–2021). PMCPA found multiple disclosure breaches and a…

2023
CASE
2021 Code Consilient Health Clause 5.1 Clause 6.1 Clause 12.1

Consilient Health: BMJ contraceptive pill ad implied unlicensed benefits and had illegible prescribing information (AUTH/3731/1/23)

A BMJ print ad/infographic funded by Consilient said contraceptive pills help skin issues, “balancing hormones” and menstrual cycles. PMCPA found this implied…

2022
CASE
2021 Code Daiichi Sankyo UK Clause 2 Clause 5.1 Clause 6.1

Daiichi Sankyo press release on Nilemdo/Nustendi: combination claim found misleading due to missing simvastatin contraindication (AUTH/3673/7/22)

A Nilemdo press release said it “can be combined with other oral treatments” but didn’t make the simvastatin >40mg contraindication immediately apparent.…

2023
CASE
2021 Code Consilient Health Clause 5.1 Clause 6.1 Clause 12.1

Consilient Health: BMJ contraceptive “infographic” ad ruled misleading and PI illegible (AUTH/3731/1/23)

BMJ print ad implied contraceptive pills were licensed to help skin issues, “balance hormones” and manage cycles, without qualification. Panel also found…

2022
CASE
2021 Code Janssen-Cilag

AUTH/3701/10/22: Astellas v Janssen — Erleada nurse support service (package deal) found not to be an inducement (No breach)

Astellas alleged Janssen’s Erleada nurse support service (offered as a package deal) induced prescribing. Panel found Astellas hadn’t evidenced wrongdoing; benefits were…

2022
CASE
2021 Code Daiichi Sankyo UK Clause 2 Clause 5.1 Clause 6.1

Daiichi Sankyo press release on Nilemdo/Nustendi: combination claim found misleading due to missing simvastatin contraindication (AUTH/3673/7/22)

A UK press release said Nilemdo “can be combined with other oral treatments” but didn’t make the simvastatin >40mg contraindication immediately apparent.…

2022
CASE
2021 Code SOBI

Sobi sponsored Guardian haemophilia article: no breach (AUTH/3696/10/22)

Anonymous complaint alleged a Guardian-sponsored corporate article was disguised promotion and misleading. PMCPA Panel ruled no breach of Clauses 3.6, 5.1, 6.1,…

2022
CASE
2021 Code Janssen-Cilag

AUTH/3701/10/22: Astellas v Janssen — Nurse support service for Erleada (apalutamide) offered as a package deal (No breach)

Astellas alleged Janssen’s Erleada nurse support service (package deal) induced prescribing. The Panel found Astellas did not evidence wrongdoing and ruled no…

111121314151617129

Ask questions about any PMCPA case

Our PMCPA rulings expert has knowledge of over 1,900 published cases — ask about precedents, clauses, and how they apply to your situation.

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free